Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박병배 | - |
dc.date.accessioned | 2018-02-26T07:22:03Z | - |
dc.date.available | 2018-02-26T07:22:03Z | - |
dc.date.issued | 2016-03 | - |
dc.identifier.citation | THORACIC CANCER, v. 7, NO 2, Page. 207-214 | en_US |
dc.identifier.issn | 1759-7706 | - |
dc.identifier.issn | 1759-7714 | - |
dc.identifier.uri | http://onlinelibrary.wiley.com/doi/10.1111/1759-7714.12315/abstract;jsessionid=95B3735D3691ADC88B875EA4C39EF165.f02t03?systemMessage=Please+be+advised+that+we+experienced+an+unexpected+issue+that+occurred+on+Saturday+and+Sunday+January+20th+and+21st+that+caused+the+site+to+be+down+for+an+extended+period+of+time+and+affected+the+ability+of+users+to+access+content+on+Wiley+Online+Library.+This+issue+has+now+been+fully+resolved.++We+apologize+for+any+inconvenience+this+may+have+caused+and+are+working+to+ensure+that+we+can+alert+you+immediately+of+any+unplanned+periods+of+downtime+or+disruption+in+the+future. | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/40636 | - |
dc.description.abstract | BackgroundTo investigate the efficacy, safety, and tolerability of weekly docetaxel treatment in advanced non-small cell lung cancer (NSCLC) patients in Korea. MethodsThis prospective observational study included Korean advanced NSCLC patients with Eastern Cooperative Oncology Group performance status <2 who received weekly monotherapy of docetaxel at a dose determined by the physician. Efficacy measurements included tumor response rate, overall survival (OS), progression-free survival, and one-year survival rate. Safety was analyzed through recorded incidences of adverse events (AEs), serious adverse events (SAEs), deaths, and other related safety parameters, along with their toxicity grades. Results:Of 274 patients analyzed, one patient achieved a complete response and 42 partial responses; thus, the overall response rate was 15.7%. The OS rate at baseline and at one-year follow-up was 38.3% and 33.8%, respectively. AEs were reported in 229 (83.6%) patients. The most frequently reported hematologic AE of grade 3 was a decrease in neutrophils, with 6.6% of the patients developing neutropenia. In non-hematologic AEs of grade 3, the most common were infection with unknown absolute neutrophil count and death not associated with Common Terminology Criteria for Adverse Events (CTCAE) (4.7% each). The most common SAE reported was death, not associated with CTCAE (7.3%). ConclusionsIn Korean patients, the weekly regimen of docetaxel monotherapy was safe and efficacious against advanced NSCLC. | en_US |
dc.description.sponsorship | This study was sponsored by Sanofi-Aventis Korea Ltd. | en_US |
dc.language.iso | en | en_US |
dc.publisher | WILEY-BLACKWELL | en_US |
dc.subject | Carcinoma | en_US |
dc.subject | docetaxel | en_US |
dc.subject | non-small cell lung cancer | en_US |
dc.subject | safety | en_US |
dc.title | Safety and efficacy of single-agent docetaxel (Taxotere) administered weekly in non-small cell lung carcinoma patients in Korea: An observational study | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 7 | - |
dc.identifier.doi | 10.1111/1759-7714.12315 | - |
dc.relation.page | 207-214 | - |
dc.relation.journal | THORACIC CANCER | - |
dc.contributor.googleauthor | Lim, Sun Min | - |
dc.contributor.googleauthor | Park, Byeong Bae | - |
dc.contributor.googleauthor | Park, Keun-Chil | - |
dc.contributor.googleauthor | Kim, Hoon-Kyo | - |
dc.contributor.googleauthor | Lee, Jong Seok | - |
dc.contributor.googleauthor | Bae, Sung Hwa | - |
dc.contributor.googleauthor | Lee, Seung-Sei | - |
dc.contributor.googleauthor | Kang, Jin-Hyoung | - |
dc.contributor.googleauthor | Park, Se-Hoon | - |
dc.contributor.googleauthor | Lee, Gyeong-Won | - |
dc.relation.code | 2016008644 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | bbpark | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.